找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Immunotherapy for Gastrointestinal Malignancies; Ramakrishna Vadde,Ganji Purnachandra Nagaraju Book 2020 The Editor(s) (if applicable) and

[復(fù)制鏈接]
樓主: 驅(qū)逐
31#
發(fā)表于 2025-3-27 00:01:48 | 只看該作者
32#
發(fā)表于 2025-3-27 04:23:02 | 只看該作者
Tumor Heterogeneity: Challenges and Perspectives for Gastrointestinal Cancer Therapy,son for the low treatment response rate in cancer patients. Thus, there is always a quest to understand the tumor heterogeneity in any cancer type. In this chapter, the authors attempted to understand the types and drivers for tumor heterogeneity, especially in gastrointestinal cancers, and discusse
33#
發(fā)表于 2025-3-27 05:35:34 | 只看該作者
Immunocomposition of Gastrointestinal Tract of Gut,rwhelming load of antigens in the form of dietary antigens on a daily basis. The GI tract has played dual role in the body, in that it performs uptake of nutrients and digestion while also performing out the complex and principal task of maintaining immune homeostasis, i.e., maintaining the balance
34#
發(fā)表于 2025-3-27 11:43:56 | 只看該作者
35#
發(fā)表于 2025-3-27 16:05:21 | 只看該作者
36#
發(fā)表于 2025-3-27 19:34:49 | 只看該作者
Immune Cell Therapy Against Gastrointestinal Tract Cancers, the healthcare sector across the globe. Recently advancements in high throughput techniques provide us with a unique opportunity to detect biomarkers and treat various diseases, including GI cancer, more comprehensively. However, most of these approaches are ineffective for treating patients with a
37#
發(fā)表于 2025-3-28 01:23:56 | 只看該作者
Immune Checkpoint Inhibitors in Gastrointestinal Malignancies,se of cancer related deaths. GI cancers are treated by surgery, radiotherapy, and chemotherapy. The overall survival rate (5 years of survival) after the surgery is very poor in patients with GI cancers. To increase the survival rate adjuvant therapies like chemotherapy and radiotherapy were perform
38#
發(fā)表于 2025-3-28 05:57:20 | 只看該作者
39#
發(fā)表于 2025-3-28 06:33:32 | 只看該作者
40#
發(fā)表于 2025-3-28 11:12:25 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-25 22:05
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
织金县| 红原县| 涿鹿县| 宁波市| 裕民县| 乌苏市| 盈江县| 中山市| 五家渠市| 丹江口市| 沙洋县| 缙云县| 阳城县| 隆回县| 五常市| 南涧| 长寿区| 安庆市| 界首市| 安乡县| 乌鲁木齐市| 象山县| 双桥区| 莱州市| 出国| 彰化市| 色达县| 常熟市| 陵川县| 健康| 沁水县| 山西省| 五指山市| 喀喇| 陵水| 浦县| 罗甸县| 武冈市| 基隆市| 政和县| 上饶市|